BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34497363)

  • 1. Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status.
    Naso JR; Tessier-Cloutier B; Senz J; Huntsman DG; Churg A
    Mod Pathol; 2022 Jan; 35(1):77-81. PubMed ID: 34497363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations.
    Salisbury T; Churg A
    Virchows Arch; 2021 Nov; 479(5):1047-1050. PubMed ID: 33721119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
    Cigognetti M; Lonardi S; Fisogni S; Balzarini P; Pellegrini V; Tironi A; Bercich L; Bugatti M; Rossi G; Murer B; Barbareschi M; Giuliani S; Cavazza A; Marchetti G; Vermi W; Facchetti F
    Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations.
    Ren HZ; Cheung S; Churg A
    Hum Pathol; 2020 Nov; 105():31-36. PubMed ID: 32916162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UHRF1 Immunohistochemical Staining Separates Benign Reactive Spindle Cell Mesothelial Proliferations From Sarcomatoid Mesotheliomas.
    Yang H; Cheung S; Churg A
    Am J Surg Pathol; 2022 Jun; 46(6):840-845. PubMed ID: 34772842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
    Chapel DB; Hornick JL; Barlow J; Bueno R; Sholl LM
    Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 immunohistochemical staining to separate benign from malignant mesothelial proliferations.
    Pors J; Naso J; Berg K; Churg A
    Mod Pathol; 2020 Feb; 33(2):312-318. PubMed ID: 31685964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
    Naso JR; Tsuji S; Churg A
    Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas.
    Bernardi L; Bizzarro T; Pironi F; Szymczuk S; Buda R; Fabbri E; Di Claudio G; Rossi G
    Cancer Cytopathol; 2021 Apr; 129(4):275-282. PubMed ID: 33045147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
    Derakhshan F; Ionescu D; Cheung S; Churg A
    Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
    Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
    Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
    Capkova L; Koubkova L; Kodet R
    Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.
    Hinterberger M; Reineke T; Storz M; Weder W; Vogt P; Moch H
    Mod Pathol; 2007 Feb; 20(2):248-55. PubMed ID: 17361207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
    Hwang HC; Pyott S; Rodriguez S; Cindric A; Carr A; Michelsen C; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 May; 40(5):714-8. PubMed ID: 26900815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
    Naso JR; Churg A
    Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples.
    Monaco S; Mehrad M; Dacic S
    Adv Anat Pathol; 2018 Jan; 25(1):24-30. PubMed ID: 29227332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
    Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
    Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.